跳到正文
原文
Medical Xpress·· 8 天前精选AI 评分75

BNP可能不仅作为心脏压力的标志物,还直接促进血栓形成

More than a warning sign: Common cardiovascular biomarker may contribute to disease

AI 导读

研究人员发现BNP通过激活血小板促进血栓形成,这为心血管疾病的治疗提供了新的靶点。研究揭示BNP不仅作为心脏压力的标志物,还直接促进血栓形成,为心血管疾病的治疗提供了新的靶点。

推荐理由

研究揭示BNP不仅作为心脏压力的标志物,还直接促进血栓形成,为心血管疾病的治疗提供了新的靶点。

正文 · 原文
heart problem
Credit: Marta Branco from Pexels

Heart disease is the leading cause of death in the United States, claiming a life nearly every 34 seconds. A major driver of these fatalities is heart failure, a progressive condition where the heart struggles to pump enough blood throughout the body.

To identify heart failure, doctors regularly test for a specific hormone in the blood called B-type natriuretic peptide, or BNP. Elevated levels of BNP and its related protein fragments have served as a biological "check engine light"—a warning sign, or biomarker, indicating the heart muscle is under stress from heart failure or another cardiovascular disease.

Researchers with the Texas A&M University Irma Lerma Rangel College of Pharmacy at Texas A&M Health have discovered that BNP could be doing far more than signaling distress. Led by Zhenyu Li, Ph.D., a professor of pharmaceutical sciences, the research team discovered that high levels of BNP actively drive blood platelets to clump together, directly accelerating the formation of blood clots and blockages.

What makes this discovery so surprising?

Medical professionals have generally viewed BNP as a messenger of cardiac stress, helping them diagnose cardiovascular disease, according to Harvard Health. However, Li's lab suspected there was more to the story.

"We thought that BNP might not only act as a passive marker but actively contribute to the pathogenesis and progression of cardiovascular disease," Li said.

The recently published study demonstrates that BNP promotes platelet activation and thrombus formation, which can lead to serious health issues such as heart attacks. The breakthrough represents decades of careful investigation, Li noted. The findings are published in the Blood Journal.

"It has been an ongoing, gradual progression—not a sudden breakthrough, but a logical continuation of our research over the past two decades," he said.

How does BNP contribute to clotting?

When blood vessels are damaged by trauma like cuts or scrapes, platelets rush to the site and clump together to stop the bleeding. However, when platelets become hyperactive, they form clots inside the blood vessels—even without an external injury—that block blood flow, preventing red blood cells from carrying out their main job of delivering oxygen to tissues and organs, according to the American Society of Hematology.

Li's team uncovered a molecular chain reaction that can lead to this hyperactive behavior. In this reaction, the BNP hormone binds directly to a specialized surface receptor on platelets known as natriuretic peptide receptor-A, or NPRA.

"It was previously unknown whether platelets even expressed this receptor," Li explained. "We are the first team to investigate whether BNP directly activates platelets through the NPRA receptor."

When BNP binds to NPRA, it elevates a signaling molecule called cyclic GMP (cGMP) inside platelets. This spark triggers a suite of pro-clotting behaviors—boosting platelet aggregation and clot growth. In studies of vascular injury and pulmonary embolism, elevated BNP markedly accelerated clot formation.

Conversely, when NPRA receptors were absent or blocked, BNP lost its ability to raise cGMP or activate platelets, preventing abnormal clot formation and maintaining healthy blood flow. The team confirmed these findings in blood samples of people with heart rhythm disorders, showing that circulating BNP levels directly correlate with platelet activity in these patients. Simply put, BNP's ability to drive blood clotting depends on its interaction with these specific NPRA receptors on platelets.

"Knocking out the NPRA gene protected against these complications, proving the clotting process is mediated by the NPRA receptor," Li said.

What does this mean for patients?

The discovery provides a biological explanation for why patients with high BNP levels face significantly elevated risks of severe cardiovascular events like heart attacks and pulmonary embolisms. More importantly, this new understanding could unlock the potential for researchers to develop safer, more specific therapies.

Standard antiplatelet medications suppress blood clotting globally throughout the body, carrying a persistent risk of dangerous internal bleeding. By focusing on the BNP–NPRA pathway, pharmaceutical developers can design targeted therapies that prevent BNP-driven clot formation without impairing the body's general ability to heal injuries, Li said.

Until these targeted therapies are available, however, Li's research suggests physicians may need to closely monitor patients with elevated BNP and consider whether antiplatelet therapy could help prevent or reduce the risk of blood clots and related complications.

What comes next?

The team plans to develop genetically modified animal models in which NPRA is selectively removed from platelets or other specific cell types. These studies will help determine if platelet NPRA is the primary driver of BNP-induced thrombosis.

"Platelets appear to be major contributors, and to confirm this further, we need to develop tissue-specific models," Li said.

The collaborative study was co-led by Li, Fadi T. Khasawneh, Yinan Wei and Fatima Z. Alshbool, faculty members at the Rangel College of Pharmacy. Yan Zhang and Guoying Zhang, also affiliated with the college, contributed as co-first authors.

The team is collaborating with Wenshe Liu, Ph.D., regents professor and Harry E. Bovay, Jr. Chair in Chemistry at the Texas A&M College of Arts and Sciences, to identify small-molecule inhibitors capable of blocking the BNP–NPRA interaction. Promising compounds will undergo further testing to determine whether they can prevent BNP-induced platelet activation and thrombosis.

Unlike current antiplatelet drugs that can disrupt overall platelet activity, homing in on this specific pathway could lay the groundwork for targeted therapies that block life-threatening blood clots while also preserving normal, healthy clotting.

"Because patients with high BNP levels face the greatest risk, targeting this pathway opens new opportunities to reduce thrombotic complications while minimizing standard side effects like severe bleeding," Li said.

Publication details

Yan Zhang et al., BNP Promotes Platelet Activation and Thrombosis via its Receptor NPRA: A Paradigm Shift from Biomarker to Effector, Blood Journal (2026). DOI: 10.1182/blood.2026035455

Journal information: Blood

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: More than a warning sign: Common cardiovascular biomarker may contribute to disease (2026, November 11) retrieved 11 November 2026 from https://medicalxpress.com/news/2026-11-common-cardiovascular-biomarker-contribute-disease.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com